Cargando…

Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy

OBJECTIVES: It has been proposed that the combination of thiazolidinedione (TZD) therapy to metformin and sulfonylurea is beneficial due to each medication having a unique mechanism of action. Within the Veterans Affairs Hospital, specific criteria of use define when TZD therapy can be initiated. Mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	McFarland, M. Shawn, Huddleston, Lana, Tammareddi, Kumar, McKenzie, Michael, Bean, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2012
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980726/ https://www.ncbi.nlm.nih.gov/pubmed/27536426 http://dx.doi.org/10.3109/21556660.2012.707996

Ejemplares similares

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
por: Hanefeld, M
Publicado: (2007)

Relationship of Oral Antihyperglycemic (Sulfonylurea or Metformin) Medication Adherence and Hemoglobin A1c Goal Attainment for HMO Patients Enrolled in a Diabetes Disease Management Program
por: Lawerence, David B., et al.
Publicado: (2006)

Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
por: Muthukrishnan, J., et al.
Publicado: (2012)

Simultaneous Estimation of Metformin and Pioglitazone by Ultraviolet Spectrophotometry
por: Goswami, Laxmi, et al.
Publicado: (2010)

Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study
por: Seong, Jong-Mi, et al.
Publicado: (2015)

Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S
por: Onishi, Yukiko, et al.
Publicado: (2015)

Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma
por: Toomey, Paul, et al.
Publicado: (2017)

Efficacy of metformin versus sulfonylurea derivative in HNF4A-MODY
por: Oosterom, Nicole, et al.
Publicado: (2022)

The Contributions of Onchocerciasis Control and Elimination Programs toward the Achievement of the Millennium Development Goals
por: Dunn, Caitlin, et al.
Publicado: (2015)

Unrecognized hemoglobin SC sickle cell disease complicated by sepsis and cholestasis
por: McFarland, Thomas, et al.
Publicado: (2022)

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
por: Roumie, Christianne L., et al.
Publicado: (2017)

The TOSCA.IT Trial: A Study Designed to Evaluate the Effect of Pioglitazone Versus Sulfonylureas on Cardiovascular Disease in Type 2 Diabetes
por: Vaccaro, Olga, et al.
Publicado: (2012)

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
por: Komajda, Michel, et al.
Publicado: (2008)

Formulation and Evaluation of Multilayered Tablets of Pioglitazone Hydrochloride and Metformin Hydrochloride
por: Chowdary, Y. Ankamma, et al.
Publicado: (2014)

Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis
por: HOU, LIQIONG, et al.
Publicado: (2015)

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
por: Mamtani, Ronac, et al.
Publicado: (2014)

Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma: erratum
Publicado: (2017)

The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review
por: Boddepalli, Chinmayi Sree, et al.
Publicado: (2022)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Improvements in Glycemic Control in Type 2 Diabetes Patients Switched From Sulfonylurea Coadministered With Metformin to Glyburide-Metformin Tablets
por: Duckworth, Wiliam
Publicado: (2003)

Development of Heart Failure in Medicaid Patients with Type 2 Diabetes Treated with Pioglitazone, Rosiglitazone, or Metformin
por: Breunig, Ian M., et al.
Publicado: (2014)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome
por: Shahebrahimi, Karoon, et al.
Publicado: (2016)

Combination of Pioglitazone and Metformin Actions on Liver Lipid Metabolism in Obese Mice
por: Liu, Jieying, et al.
Publicado: (2023)

Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
por: Carls, Ginger, et al.
Publicado: (2017)

Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus
por: George, Joe
Publicado: (2015)

Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas
por: Chu, Patricia Y., et al.
Publicado: (2020)

Development of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a Sulfonylurea
por: Baker, Matthew C., et al.
Publicado: (2023)

Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy
por: Gordon, Jason P., et al.
Publicado: (2015)

Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes
por: Esteghamati, Alireza, et al.
Publicado: (2013)

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
por: Fonseca, V, et al.
Publicado: (2011)

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients
por: Susilawati, Elis, et al.
Publicado: (2023)

Facilitators and barriers to patient-centred goal-setting in rehabilitation: A scoping review
por: Crawford, L., et al.
Publicado: (2022)

Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin
por: Peng, Xiaomei, et al.
Publicado: (2016)

Evaluation of Osteopontin Gene Expression in Endometrium of Diabetic Rat Models Treated with Metformin and Pioglitazone
por: Hosseiny, Zeinab Sadat, et al.
Publicado: (2019)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Kim, Jong Ho, et al.
Publicado: (2016)

Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis
por: Xu, Yifeng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_24tl3m6lhp06edsoo016gi2ntr